IINN News & Events

Inspira Technologies announced the termination of its sales agreement with A.G.P./Alliance Global Partners, dated February 17 and its standby equity purchase agreement with YA II PN, dated December 12, 2025. The company has delivered formal written notices to terminate these financing facilities, with no outstanding obligations or further advances to be made under either agreement by either of the parties to the respective agreements.

Inspira Technologies announced that on February 19, it received written notice from the Nasdaq Stock Market advising the company that it was not in compliance with Listing Rule 5550(b)(2) requiring companies listed on the Nasdaq Capital Market to maintain a minimum market value of publicly held shares of $35,000,000. The company has a period of 180 calendar days, or until August 18, to regain compliance. To regain compliance, the company's minimum market value of publicly held shares must close at $35,000,000 or more for a minimum of 10 consecutive business days. Inspira intends to actively monitor its minimum market value of listed securities and may, if appropriate, consider implementing available options to regain compliance.

Inspira Technologies OXY announced the deployment and initiation of a structured commercial evaluation of its U.S. Food and Drug Administration-cleared INSPIRA ART100 system at a new and additional leading U.S. academic medical center. This deployment expands Inspira Technologies' presence within the Tier-1 U.S. hospital market. The ART100 system has been integrated into the center's clinical workflow to support a structured evaluation designed to define clinical protocols and potential broader institutional adoption. This activity builds upon the Company's FDA clearance and ongoing commercial activity at other leading U.S. healthcare facilities.